Pharmacotherapy for obesity

Area of Science:

• Pharmacology
• Metabolic Disease Research
• Oncology

Background:

• Obesity is a significant risk factor for metabolic diseases and various cancers.
• Current obesity treatments include lifestyle changes, pharmacotherapy, and bariatric surgery.
• Pharmacotherapy is considered when lifestyle interventions yield modest weight loss.

Purpose of the Study:

• To review currently available anti-obesity drugs.
• To categorize pharmacotherapy agents by treatment duration (short-term vs. long-term).
• To inform healthcare providers and patients about drug options and their differing side effect profiles.

Main Methods:

• Literature review of FDA-approved anti-obesity medications.
• Categorization of drugs based on approved usage period (short-term or long-term).
• Summary of mechanisms of action and key characteristics of selected drugs.

Main Results:

• Short-term agents include sympathomimetics like phentermine, approved due to safety concerns.
• Long-term agents include orlistat (fat digestion inhibitor), lorcaserin (serotonin receptor agonist), and phentermine/topiramate combination (8-10 kg mean weight loss).
• Each drug possesses distinct side effect profiles crucial for patient selection.

Conclusions:

• A variety of pharmacotherapy options exist for obesity management.
• Drug selection should carefully consider individual patient factors and potential side effects.
• Understanding the efficacy and safety of different anti-obesity medications is essential for effective treatment.